Cassia auriculata: Aspects of Safety Pharmacology and Drug Interaction by Puranik, Amrutesh S. et al.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2011, Article ID 915240, 8 pages
doi:10.1093/ecam/nep237
Original Article
Cassiaauriculata:A s pec t so fS a f ety
Pharmacology and Drug Interaction
Amrutesh S. Puranik,1 Ganesh Halade,2 Sandeep Kumar,3 Ranjan Mogre,4 Kishori Apte,5
A s h o kD .B .V aid y a, 6 andBhushan Patwardhan1,7
1Interdisciplinary School of Health Sciences, University of Pune, Pune 411007, India
2University of Texas Health, Science Center at San Antonio, San Antonio, TX, USA
3National Center for Cell Sciences, Pune, India
4Applied Biotech, Vile Parle, Mumbai, India
5National Toxicology Center, Pune, India
6ICMR—Advanced Centre of Reverse Pharmacology, MRC-KHS, Vile Parle, Mumbai, India
7Manipal Education, Bangalore 560008, India
Correspondence should be addressed to Bhushan Patwardhan, bhushan@unipune.ernet.in
Received 8 April 2009; Accepted 12 December 2009
Copyright © 2011 Amrutesh S. Puranik et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Safety pharmacology studies help in identifying preclinical adverse drug reactions. We carried out routine safety pharmacology
withfocusoncardiovascularvariablesandpharmacokineticherb-druginteractionstudiesonratsfedwithstandardizedtraditional
hydro-alcoholicextractandtechnology-based supercriticalextractofCassiaauriculatafor12weeks. Ourstudiesindicatethatboth
these extracts are pharmacologically safe and did not show any signiﬁcant adverse reactions at the tested doses. The traditional
hydro-alcoholic extract did not show any signiﬁcant eﬀect on pharmacokinetics; however, the technology-based supercritical
extract caused a signiﬁcant reduction in absorption of metformin. Our results indicate the need to include pharmacokinetic herb-
drug interaction studies as evidence for safety especially for technology-based extracts.
1.Introduction
While the dietary botanical supplement market is growing,
the need for more rigorous clinical and scientiﬁc research
on herbal and traditional medicine is strongly advocated
for larger acceptances and visibility [1]. Traditional herbal
medicines have a long history of use and are generally
considered to be safer than synthetic drugs. Traditional
medicine-inspired approaches remain important especially
for the management of chronic diseases as well as to facilitate
natural product drug discovery [2, 3].
Combinations of herbal medicines or phytochemical
actives are found to be beneﬁcial in certain diseases when
given along with modern synthetic drugs [4]. However,
during concurrent use with modern medicines some poten-
tial adverse reactions have been reported [5, 6]. Herbal
medicines when co-administered with synthetic drugs may
result in herb-drug interactions inﬂuencing bioavailability
leading to adverse events [7]. Therefore, studies related
to safety pharmacology and pharmacokinetic herb-drug
interactions are more important when concurrent use of
herbal and modern medicine is on rise. For chronic diseases
including diabetes and cardiovascular conditions where
long-term treatment is needed, co-administration of herbal
and modern medicines may pose higher risk of adverse
events and hence suﬃcient evidence of safety is necessary
[8, 9]. In such situations, safety pharmacology is useful
to predict the adverse drug reactions [10]. Safety pharma-
cology deals with key aspects that are causal to unknown
adverseeventsandaimsatinvestigatingpotentialundesirable
pharmacodynamic eﬀects on physiological functions in the
therapeutic dose range. Increasing regulatory concerns in
drug development have broadened the scope of safety
to include general pharmacology, adverse drug reactions,
cardiovascular pharmacology and pharmacokinetic herb-
drug interactions [11]( Figure 2).
Ayurveda advocates several medicinal plants for treat-
ment of diabetes. We selected Cassia auriculata (CA) Linn,2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: (a) Pharmacokinetic herb-drug interaction study on CA-HA extracts. Data are expressed as mean ± SE obrained from n = 4
rats per three time intervals. No signiﬁcant reduction in AUCM for CA-HA when compared with metformin group versus test group.
(b) Pharmacokinetic herb-drug interaction study on CA-SFE extracts. Signiﬁcant reduction in AUCM for CA-SFE when compared with
metformin group versus test group. Signiﬁcance denoted by ∗∗P<0.01, ∗P<0.05.
family Caesalpiniaceae, also known as Tanner’s Cassia or
Avartaki in vernacular, which is used in Ayurveda in the
treatment of diabetes [12]. The ﬂower and leaf extract of
CA is shown as antihyperglycemic in streptozotocin-induced
experimental diabetes [13, 14]. Methanolic extracts of CA
ﬂowers have been demonstrated to inhibit α-glucosidase in
vivo as well as in vitro [15] .I t sa q u e o u se x t r a c ti sr e p o r t e dt o
prevent the lipid peroxidation in brain of diabetic rats [16].
Hyponidd, a formulation containing CA has been shown
as antihyperglycemic and antioxidant [17]. Polyphenols are
considered to be the active ingredients of CA [18]. Generally,
hydro-alcoholic solvent is used to extract polyphenols from
the crude herbal material. Traditional medicine practice also
generally advocates use of hydro-alcoholic (HA) extracts of
herbal materials. Yet, there is a growing practice to adopt
technology-basedsupercriticalﬂuidextracts(SFE)forhigher
yields of polyphenol [19–21] and are now widely used by the
industry [22–24]. However, technology-based extracts such
as SFE has no prior evidence of traditional use and hence we
attempted a safety pharmacology study.
Diabetes is a diﬃcult to manage disease and long-term
treatment with careful monitoring is necessary. It is known
thatmanyatimespatientstendtoexploreseveralalternatives
concurrently with anti-hyperglycemic agents such as met-
formin and insulin-sensitizing agents like thiazolidinediones
for treatment of diabetes [25]. The Food and Drug Admin-
istration has made cardiovascular safety mandatory for any
new therapeutic agents intended in the management of
diabetes[26].Therefore,whilestudyingsafetypharmacology
we focused on the cardiovascular system. We also studied the
pharmacokinetic herb-drug interaction of CA extracts with
metformin, which is the most preferred ﬁrst line treatment
of type 2 diabetes. This study is very relevant and important
because metformin is classiﬁed as a hard drug, which does
not get metabolized in the body and therefore increases
possibility of herb-drug interactions.
2.MaterialsandMethods
2.1. Plant Source. CA was collected from biological reserves
of Sangamner area, District Ahmednagar, Maharashtra,
India. Botanical authentication was carried out by qualiﬁed
person at Agharkar Research Institute, Pune, India, and a
voucher sample has been deposited at its herbarium.Evidence-Based Complementary and Alternative Medicine 3
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Figure 2: Safety pharmacology in herbal drug development.
2.2. Chemicals. All the standards including (–) epicate-
chin, (–) epicatechin gallate, procyanidin B1, (–) catechin,
phenformin hydrochloride and homocysteine were procured
from Sigma-Aldrich, USA, and the High performance liq-
uid chromatography (HPLC) solvents from Merck, India.
Metformin was obtained from LGC, Promochem, India.
Sodium carboxy methyl cellulose (NaCMC) (Merck, India)
was used as vehicle for administering CA extracts. The
kits for serum analysis of glucose, total cholesterol (TC),
triglycerides (TG), serum glutamic pyruvic transaminase
(ALT or SGPT), serum glutamic oxatoacetic transaminase
(AST or SGOT), alkaline phosphatase (ALP), blood urea
nitrogen (BUN), total proteins albumin and globulin were
purchased from Merck Ecoline, Mumbai, India. The serum
total bilirubin and creatinine were estimated using kits from
Labkit, Spain. Creatinine kinase-MB (CKMB) and troponin
I was estimated by kits from Teko diagnostics, CA, USA, and
Monobind Inc., CA, USA, respectively.
2.3. Extracts. The seeds of CA were crushed into a coarse
powder. The powder was then defatted by petroleum ether
prior subjecting it to hydro-alcoholic maceration for 7
days. The collected solvent was evaporated on a rotavapor
at 35◦C and the extract with a yield of 15% was freeze
dried. This hydro-alcoholic extract of CA (CA-HA) was used
for present study. The technology-based supercritical ﬂuid
extract of CA (CA-SFE) was prepared at Vedic Supercriticals
& Biotechnologies (I) Pvt Ltd, Pune, India. The extraction
was carried by modifying the reported method [27]. Brieﬂy,
carbon dioxide in the supercritical state at a ﬂow rate of
100kgh−1 with 3% ethyl alcohol as modiﬁer at a pressure of
300 bars at 45◦C was used for 2.5h. The yield obtained was
3.8%.
2.4. Standardization. HPLC was used for standardization.
CA-HA and CA-SFE extracts were injected into a pH stable
reverse phase C18 column (4.6 × 250mm, Varian, Varian
Inc.) pre-equilibrated with mobile phase solution containing
mobile phase A water:methanol:formic acid (79.5:20:0.5)
and B acetonitrile:formic acid (99.7:0.3) at a ﬂow rate of
0.4mL and a gradient described in Supplementary Figure
1. The chromatographic system used for all the analysis
(Dionex, Germany) consisted of P-680 quaternary gradient
pump, an ASI 100 autosampler, a universal chromatographic
interface UCI-50 and diode array detector 340U or ﬂuores-
cence detector RF-2000 integrated by Chromeleon Software
6.70. Standard curves of (–) epicatechin, (–) catechin
and procyanidin B1 are plotted and the concentration of
unknown is quantiﬁed by linear regression.
2.5. Animals. Wistar albino rats of both sexes, aged 6–8
weeks, weighing 150–220g were randomly bred in well-
controlled animal house facility of National Toxicology
Centre, Pune, India. The animals were housed in standard
conditions of temperature (22 ± 5◦C) and humidity (55 ±
15%) and 12h light-dark cycles. They were fed on con-
ventional laboratory pelleted diet and water ad libitum.A l l
the procedures were performed as per the guidelines of the
Committee for the Purpose of Control and Supervision of4 Evidence-Based Complementary and Alternative Medicine
Experiments on Animals (CPCSEA), Ministry of Animal
Welfare Division, Government of India, New Delhi, and was
approved by the Institutional Animal Ethics Committee of
National Toxicology Center, Pune, India.
2.6. Safety Studies. Animals were divided into six groups
(n = 12 per group; six males and six females). CA-SFE
and CA-HA extracts were re-suspended in 0.5% vehicle and
administered daily orally by gavages using feeding needle to
all the six groups. The control group received equal volume
of vehicle. CA-SFE was administered at three doses: 250,
500 and 1000mgkg−1 and CA-HA at two dose: 500 and
1000mgkg−1 for a period of 12 weeks. The experimental
doses were decided based on the human dose in traditional
practice [11].
2.7. Variables Monitored
2.7.1. Body Weight. Body weight of all the groups treated
with CA-SFE, CA-HA extracts and control were monitored
weekly.
2.7.2. Organ Weight. The animals were sacriﬁced at the
termination of the study. The organs such as liver, muscles,
lungs,spleen,kidney,heart,brain,adrenals,testisandovaries
wereremoved,blottedfreeofblood,weighedimmediatelyon
precision balance CA123 (Clontech, India) and stored in 4%
paraformaldehyde for subsequent histological analysis. All
the organs were embedded in paraﬃn, sectioned and stained
with hematoxylin-eosin.
2.7.3.HematologyandBiochemistry. After12hfasting,blood
was collected retro-orbitally under anesthesia. Blood was
immediatelyanalyzedforwhitebloodcells(WBC),redblood
cells (RBC), hemoglobin (HB), hematocrit (HCT), mean
corpuscular volume (MCV), mean cell hemoglobin (MCH),
mean cell hemoglobin concentration (MCHC) and platelet
count (PLT) by using an automated hematology analyzer
(Sysmex-KX-21, Kobe, Japan).
The serum was separated from blood cells by centrifuga-
tion at 2000g for 15min at 4◦C Superspin R-V/FM, Plasto
Crafts, Mumbai, India. For glucose evaluation, blood was
collected in ﬂuoride bulb to avoid glycolysis on storage. The
serum samples were stored at −20◦C until analyzed. Serum
was assayed for glucose, cholesterol, triglyceride, total biliru-
bin, ALT, AST, ALP, BUN, creatinine, total proteins, albumin
and globulin by using calibrated auto-analyzer Hitachi-
704, Boehringer Mannheim Diagnostics, Germany. Serum
homocysteine was analyzed by HPLC using a ﬂuorescence
detector [28, 29]. The limit of detection of homocysteine was
500nmolL−1.
2.7.4. Cardiovascular Studies. After 12 weeks of dosing CA
extracts, rats were anesthetized with urethane (1gkg−1 body
weight). The right carotid artery was cannulated with a
microtip pressure transducer (SPR-671, Millar Instruments)
connected to an electrostatic chart recorder. The transducer
was advanced into the left ventricle for the evaluation of ven-
tricular pressures (systolic and diastolic) and heart rate were
monitored and recorded using Chart 5.5 (ADI Instruments,
Australia). Rectal temperature was maintained at 36–38◦C
throughouttheprocedure[30].Troponin,homocysteineand
CKMB were identiﬁed as biochemical markers for heart
damage.
2.8. Pharmacokinetic Herb-Drug Interaction. In the con-
trol group, the pharmacokinetics of metformin at dose
of 500mgkg−1 was studied. In the test groups, CA-SFE
at 250, 500 and 1000mgkg−1 and CA-HA at 500 and
1000mgkg−1 dose were orally co-administered with met-
formin (500mgkg−1). Male wistar rats (n = 4 rats per three
time interval, i.e., 28 rats per group) weighing 150–200g
were randomized. Blood (150μL) was collected at speciﬁed
time (Figure 1) intervals over a period of 48h. Plasma was
s e p a r a t e df r o mb l o o da n ds t o r e da t−30◦C until metformin
a s s a y .T h ea r e au n d e rc u r v ef o rm e t f o r m i n( A U C M)w a s
calculated in all the groups. AUCM in control group was
compared with AUCM in test groups. A decrease in AUCM
test versus AUCM control was interpreted as the herb-
drug interaction. Metformin was estimated using previously
reported methods with phenformin as internal standard
[31]. The limit of detection for metformin in plasma was
50ngmL−1.
2.9. Statistical Analysis. The data were expressed as the mean
± SD obtained for safety studies. Signiﬁcance was tested
using ANOVA followed by Dunnett’s multiple comparison
test. For metformin analysis, linear regression analysis was
used to ﬁnd concentration of metformin at diﬀerent time
points in plasma. Mean of AUC ± SEM was calculated using
GraphPad Prism version 4.00 for Windows, GraphPad Soft-
ware, USA. Statistical signiﬁcance was accepted at P < 0.05.
3. Results
3.1. Phytochemical Standardization. CA extracts are stan-
dardized for polyphenols based on the relative retention
and spectra match. Polyphenols such as (–) epicatechin,
procyanidin B1 and (–) catechin were quantiﬁed in CA-HA
extract (Supplementary Figure 1), while (–) catechin and (–)
epicatechin gallate in CA-SFE extract (Supplementary Figure
2). Polyphenols quantiﬁed in CA-HA are epicatechin (14%),
catechin (4.5%) and procyanidin B1 (1%), while CA-SFE
contains catechin (6%) and epicatechin gallate (20%).
3.2. Safety Pharmacology. No mortality was observed during
the treatment period of 12 weeks in either the control or
treated groups. The animals did not show any changes in
general behavior and physiological activities. No change was
observed in the body and organ weight between control
and CA-dosed animals of both sexes. No signiﬁcant changes
in the blood hematological values were observed (Supple-
mentary Table 1). No signiﬁcant changes in the diﬀerential
counts were observed (Supplementary Table 2). Male rats
dosed with 1000mgkg−1 of CA-SFE demonstrate 30 andEvidence-Based Complementary and Alternative Medicine 5
Table 1: Cardiovascular risk markers demonstrating cardiovascular safety of CA dosed animals.
Control (0.5% NaCMC)
C. auriculata (mgkg−1)
HA SFE
500 1000 250 500 1000
Male
Homocysteine (μmolL−1) 10.2 ± 1.52 9.5 ± 2.15 5.8 ± 1.51∗∗ 7.7 ± 1.66 7.8 ± 3.10 5.5 ± 3.09∗∗
CKMB (IUL−1) 141.6 ± 26.65 143.8 ± 33.21 120.5 ± 20.0 135.7 ± 13.33 125.6 ± 31.55 120.4 ± 13.66
Troponin I (ngmL−1)0 . 6 4 ± 0.03 0.67 ± 0.05 0.56 ± 0.10 0.48 ± 0.09 0.61 ± 0.08 0.55 ± 0.06
Female
Homocysteine (μmol L−1) 11.0 ± 2.52 10.0 ± 1.52 6.6 ± 1.74∗ 6.9 ± 1.35 9.2 ± 1.85 6.5 ± 2.14∗
CKMB (IUL−1) 150.2 ± 30.27 138.9 ± 24.22 133.8 ± 15.88 145.5 ± 33.20 132.2 ± 30.9 135.5 ± 16.3
Troponin I (ngmL−1)0 . 5 1 ± 0.10 0.47 ± 0.07 0.56 ± 0.09 0.55 ± 0.04 0.55 ± 0.03 0.67 ± 0.04
Data are expressed as mean ± SD, n = 6. ∗P<0.05, ∗∗P<0.01 signiﬁcant decrease in homocysteine seen by 1000mgkg−1 dose of CA-HA and CA-SFE.
Table 2: Ventricular pressures of CA-dosed animals.
Control (0.5% NaCMC)
C. auriculata (mgkg−1)
Ventricular pressures (mmHg) HA SFE
500 1000 250 500 1000
Male
Systolic blood pressure 124.2 ± 6.2 119.4 ± 9.6 117.2 ± 4.7 121.3 ± 8.1 113.1 ± 11.2 121.9 ± 3.2
Diastolic blood pressure 83.2 ± 4.3 81.0 ± 3.4 79.5 ± 4.0 82.1 ± 4.8 79.2 ± 7.01 81.9 ± 6.4
Female
Systolic blood pressure 119.3 ± 8.21 116.2 ± 3.9 118.7 ± 3.8 120.1 ± 11.5 116.9 ± 9.21 118.3 ± 9.8
Diastolic blood pressure 78.3 ± 6.2 77.3 ± 4.1 81.8 ± 2.9 79.9 ± 3.9 81.2 ± 4.01 77.4 ± 8.3
Data are expressed as mean ± SD, n = 6. No signiﬁcant diﬀerence ventricular pressures seen at increasing doses of both CA-HA and CA-SFE.
12% increase in ALT and ALP, respectively (Supplementary
Table 3). In the female group, on dosing with CA-SFE at
250mgkg−1 a decrease in the AST by 34% was observed.
No signiﬁcant change in total bilirubin, TC, TG, glucose and
creatinine were observed.
3.3. Cardiovascular Safety. An increase in dose of CA
extracts caused a signiﬁcant decrease in serum homocysteine
(P < 0.01) (Table 1). A reduction of 10% was also seen
in CK-MB in 1000mgkg−1 dose of both CA-HA and CA-
SFE. However, there was no signiﬁcant change in troponin.
Therewasnosigniﬁcantdiﬀerencebetweenbothsystolicand
diastolic blood pressure between CA extract-dosed animals
and controls (Table 2). ECG variables like heart rate (R-R
interval), QT interval (diastolic dysfunction) and ventricular
hypertrophy (R wave amplitude) were normal in all the
groups (Table 3).
3.4. Pharmacokinetic Herb-Drug Interaction. CA-SFE ex-
tracts at a dose of 1000mgkg−1 when co-administered
with metformin decreased the AUCM by 60% than the
metformin alone (P < 0.01). At the same dose the maximum
concentration (Cmax) of metformin was decreased by 55%.
At a dose of 250 and 500mgkg−1 CA-SFE decreased AUCM
by 33 (P < 0.05) and 30%, respectively (Figure 1(b)). CA-
HA extracts at doses of 500 and 1000mgkg−1 did not sig-
niﬁcantly change in AUCM as compared with the metformin
group (Figure 1(a)). There was no signiﬁcant change in
blood glucose when compared between metformin- and CA-
treated groups.
4. Discussion
Ethnopharmacology and traditional knowledge-inspired
approaches have been useful in drug discovery and devel-
opment [32, 33]. While many traditional herbal medicines
available in the market use diﬀerent types of extracts,
Indian FDA prohibits use of solvents except hydro-alcohol
in traditional Ayurvedic formulations. The advantage of
traditional knowledge in herbal drug development becomes
relevant and useful only when the traditional processes
are strictly adopted. Use of any modern technology or
solvents to prepare puriﬁed or beneﬁciated extracts may be
needed and desirable; however, this needs to be considered
as a deviation from traditional processes. The extracts or
herbal drugs prepared as per traditional processes may be
accepted to be generally safe. However, technology based
and/or solvent extracts need to be treated as new entities
and therefore they should not be generally considered as
safe. Due to new extraction technologies use of concentrates,
actives and total or crude extracts are becoming popular and
economical. However, whether such new technology-based
extracts can or should replace the traditional extraction
p r o c e s s e si ss t i l ld e b a t a b l e[ 34]. It is advocated that detailed
safety and herb-drug interaction studies are necessary before
such new extracts are used in herbal formulations. Over6 Evidence-Based Complementary and Alternative Medicine
Table 3: Electro-cardiograms (ECG) variables demonstrating cardiovascular safety of CA extracts.
Control (0.5% NaCMC)
C. auriculata (mgkg−1)
HA SFE
500 1000 250 500 1000
Males
QT interval(s) 7.0 ± 1.2 7.1 ± 1.5 6.5 ± 0.6 7.0 ± 0.5 7.5 ± 0.3 6.8 ± 2.5
Rw a v ea m p l i t u d e( μV) 225 ± 66 250 ± 65 200 ± 69 250 ± 55 300 ± 54 350 ± 48
R-R interval(s) 0.3 ± 0.01 0.25 ± 0.01 0.22 ± 0.05 0.29 ± 0.03 0.22 ± 0.08 0.28 ± 0.09
Females
QT interval(s) 7.5 ± 1.9 6.0 ± 1.0 7.2 ± 0.4 7.2 ± 0.8 7.9 ± 0.9 6.0 ± 1.2
Rw a v ea m p l i t u d e( μV) 255 ± 92 220 ± 55 255 ± 169 253 ± 68 210 ± 120 220 ± 96
R-R interval(s) 0.22 ± 0.02 0.19 ± 0.02 0.20 ± 0.03 0.23 ± 0.03 0.29 ± 0.05 0.30 ± 0.09
Data are expressed as mean ± SD, n = 6. No signiﬁcant diﬀerence in heart rate (R-R interval), QT interval (diastolic dysfunction) and ventricular hypertrophy
(R wave amplitude) observed at increasing doses of both CA-HA and CA-SFE demonstrates safety of CA extracts.
this background, the present exploratory study was under-
taken on two extracts of Ayurvedic medicinal plant. We
suggest a diﬀerential development strategy for traditional
and technology-based extracts [35].
We studied safety pharmacology and pharmacokinetic
herb-drug interaction of CA extracts at diﬀerent doses for 12
weeks. Our observations indicate that the test substances did
not signiﬁcantly alter general physiology, body weight, food
consumption, diﬀerential count and hematology. Both CA
and metformin are anti-hyperglycemic agents and therefore
the blood glucose in control and experimental groups
may not have signiﬁcantly changed. The CA-HA was well
toleratedwithoutanyadverseeventsinbothmaleandfemale
rats. There was an increase in liver enzymes, ALT and ALP,
in male rats fed on highest dose of CA-SFE. This increase
can be classiﬁed as level 2 of the drug-induced liver injury
(DILI) (a criterion used for human drug safety studies based
on the percentage increase (>25–50%) in the liver enzyme
levels), which is not considered to be clinically relevant [36].
Total bilirubin, which is the actual measure of liver function,
was not altered in males and females. Liver histopathological
ﬁndings for focal necrosis and cellular inﬁltration were
negativeinbothsexes.Takentogether,thestudysuggeststhat
both extracts of CA are safe.
Cardiovascular safety for newer therapeutic agents has
been made mandatory by the FDA. Organ-speciﬁc safety
studies for drugs for treatment or prevention of type 2
diabetes is also under consideration by the FDA. Anti-
diabetic activities of CA are known in the literature [37,
38]; however, its cardiovascular eﬀects have not yet been
evaluated. The ECG examinations demonstrated normal
cardiac repolarization (QT interval), normal heart rate and
no signs of ventricular hypertrophy. Our results indicate the
heart function to be normal and rules out any occult cardiac
dysfunction.
Troponin I increase during heart failure is predictive
of mortality and ventricular rhythm abnormalities. Inﬂam-
matory conditions with heart muscle involvement termed
as myopericarditis and cardiomyopathy increases troponin
I. Recent literature suggests troponin I as better predictive
marker than CKMB [39, 40]. Thus, homocysteine, troponin
I and CKMB were considered as markers for cardiovascular
risk.Inourstudy,troponinIandCKMBdidnotdemonstrate
clinically relevant changes; however, a signiﬁcant decrease in
homocysteine indicates a causal relation. These eﬀects on the
cardiovascular system may be attributed to polyphenols and
call for detailed investigations using suitable animal models
[41].
The pharmacokinetic herb-drug interaction is an impor-
tant aspect which needs be included in safety pharmacology
studies (Figure 2). It is predicated that herb-drug interac-
tions may be under-reported, under-estimated and probably
may occur more frequently than the drug-drug interaction
[42]. The CA-HA extract when co-administered with met-
formin did not interfere with pharmacokinetics. However,
co-administration with CA-SFE extract at 250 (P < 0.05),
500 (P < 0.01) and 1000mgkg−1 (P < 0.05) decreased met-
formin concentration, at the earliest time point of 15min.
This trend continues in CA-SFE 500 and 1000mgkg−1.
In CA-SFE 500mgkg−1 the Cmax of metformin is delayed
by 1.5h; however; in CA-SFE 1000mgkg−1 there is a
signiﬁcant (P < 0.01) decrease in metformin’s Cmax indi-
cating inhibition in metformin’s absorption (Figure 1(b)).
This clearly suggests that the CA-SFE interferes with the
absorption of metformin which can be explained by the
presence of non-polar components. Metformin has negli-
gible plasma protein binding and it undergoes active renal
tubular excretion by organic cation transporter (OCT2).
Modulation of OCT2 would have changed the elimi-
nation pattern; however, we did not observe any such
changes when co-administered with metformin. Hence, it
is recommended that co-administration of CA-SFE with
modern medicine should be avoided unless supporting
evidence base especially on safety and pharmacokinetics is
available.
Our study indicates that preclinical safety pharmacology
is needed to avoid clinical adverse drug reactions. For herbal
drug development, pharmacokinetic herb-drug interaction
studies should form an integral part of safety studies. We
suggest that safety of technology-based extracts cannot be
assumed especially when it amounts to major deviation from
the traditional process. Such extracts should be treated asEvidence-Based Complementary and Alternative Medicine 7
newer entities, and basic safety and pharmacokinetic herb-
drug interaction studies are desirable.
Supplementary Data
Supplementary data are available at eCAM online.
Funding
Authors thank The Lady Tata Memorial Trust, Mumbai,
India, (http://www.dorabjitatatrust.org/) that provided part
funding through contingency for this work; remaining
funding has come through respective institutions where the
w o r kw a sc a r r i e do u t .S u p e r c r i t i c a le x t r a c t sw e r ep r e p a r e da t
gratis by Vedic Supercriticals & Biotechnologies (I) Pvt. Ltd,
Pune, under supervision (R. Mogre and A. S. Puranik).
Acknowledgments
The authors are thankful to Dr Ashok J. Amonkar, Scientist,
K.H.S, Mumbai, for phytochemistry standardization studies;
DrSandhyaSitaswad,ScientistD,NCCS,Pune,forextending
facilities for cardiovascular studies. They thank University
of Pune; NCCS, Pune; KHS, Mumbai; Vedic Supercriticals
& Biotechnologies (I) Pvt. Ltd and National Toxicology
Center, Pune, for facilities and support. R.M. is professional
consultant to Vedic Supercriticals & Biotechnologies (I) Pvt.
Ltd. This company prepared supercritical extracts as per
our requirements and supplied gratis. Our studies indicate
that such extracts may not be used directly even if they are
derived from known safe medicinal plant if the methodology
of extraction is not traditionally used. Despite this study
may not help the consultant or company, he has agreed to
coauthor this article in the larger academic interests.
References
[1] E. L. Cooper, “eCAM: clinical analyses and increasing visibil-
ity,” Evidence-Based Complementary and Alternative Medicine,
vol. 6, no. 1, pp. 1–2, 2009.
[2] B. Patwardhan, A. D. B. Vaidya, and M. Chorghade, “Ayurveda
and natural products drug discovery,” Current Science, vol. 86,
no. 6, pp. 789–799, 2004.
[3] B. Patwardhan and R. A. Mashelkar, “Traditional medicine-
inspiredapproaches todrug discovery: can Ayurveda showthe
way forward?” Drug Discovery Today, vol. 14, no. 15-16, pp.
804–811, 2009.
[ 4 ]S .L .B a d o l e ,N .M .P a t e l ,P .A .T h a k u r d e s a i ,a n dS .L .
Bodhankar, “Interaction of aqueous extract of pleurotus
pulmonarius (Fr.) Quel-Champ. with glyburide in alloxan
induced diabetic mice,” Evidence-Based Complementary and
Alternative Medicine, vol. 5, no. 2, pp. 159–164, 2008.
[5] A. Dasgupta, M. Hovanetz, M. Olsen, A. Wells, and J. K.
Actor, “Drug-herb interaction: eﬀe c to fS tJ o h n ’ sw o r to n
bioavailability and metabolism of procainamide in mice,”
Archives of Pathology and Laboratory Medicine, vol. 131, no. 7,
pp. 1094–1098, 2007.
[6] G. Calapai and A. P. Caputi, “Herbal medicines: can we
do without pharmacologist?” Evidence-Based Complementary
and Alternative Medicine, vol. 4, no. 1, pp. 41–43, 2007.
[7] X.-X. Yang, Z.-P. Hu, W. Duan, Y.-Z. Zhu, and S.-F. Zhou,
“Drug-herb interactions: eliminating toxicity with hard drug
design,” Current Pharmaceutical Design, vol. 12, no. 35, pp.
4649–4664, 2006.
[8] G. Valli and E.-G. V. Giardina, “Beneﬁts, adverse eﬀects
and drug interactions of herbal therapies with cardiovascular
eﬀects,” Journal of the American College of Cardiology, vol. 39,
no. 7, pp. 1083–1095, 2002.
[9] P.Goldman,“Herbalmedicinestodayandtherootsofmodern
pharmacology,”AnnalsofInternalMedicine,vol.135,no.8,pp.
594–600, 2001.
[10] M.K.Pugsley,S.Authier,andM.J.Curtis,“Principlesofsafety
pharmacology,” British Journal of Pharmacology, vol. 154, no.
7, pp. 1382–1399, 2008.
[11] J.-P. Valentin and T. Hammond, “Safety and secondary phar-
macology: successes, threats, challenges and opportunities,”
Journal of Pharmacological and Toxicological Methods, vol. 58,
no. 2, pp. 77–87, 2008.
[12] V. Gogte, “Medicinal plants,” in Ayurvedic Pharmacology and
Therapeutic Uses of Medicinal Plants (Dravyagunavignyan),S .
Ramakrishnan, Ed., p. 840, Bhartiya Vidya Bhavan, Mumbai,
India, 2000.
[13] M. Latha and L. Pari, “Antihyperglycaemic eﬀect of Cassia
auriculata in experimental diabetes and its eﬀects on key
metabolic enzymes involved in carbohydrate metabolism,”
Clinical and Experimental Pharmacology and Physiology, vol.
30, no. 1-2, pp. 38–43, 2003.
[14] S. Gupta, S. B. Sharma, S. K. Bansal, and K. M. Prabhu,
“Antihyperglycemic and hypolipidemic activity of aqueous
extract of Cassia auriculata L. leaves in experimental diabetes,”
Journal of Ethnopharmacology, vol. 123, no. 3, pp. 499–503,
2009.
[15] K. J. M. Abesundara, T. Matsui, and K. Matsumoto, “α-
glucosidase inhibitory activity of some Sri Lanka plant
extracts, one of which, Cassia auriculata, exerts a strong
antihyperglycemic eﬀect in rats comparable to the therapeutic
drug acarbose,” Journal of Agricultural and Food Chemistry,
vol. 52, no. 9, pp. 2541–2545, 2004.
[16] M. Latha and L. Pari, “Preventive eﬀects of Cassia auriculata
L. ﬂowers on brain lipid peroxidation in rats treated with
stretozocin,” Molecular and Cellular Biochemistry, vol. 243, no.
1-2, pp. 23–28, 2003.
[17] P. S. Babu and P. S. M. Prince, “Antihyperglycaemic and
antioxidant eﬀect of hyponidd, an ayurvedic herbomineral
formulation in streptozotocin-induced diabetic rats,” Journal
ofPharmacyandPharmacology,vol.56,no.11,pp.1435–1442,
2004.
[18] R. Paris and B. Cubukcu, “Presence of leucoanthocyanic
chromogens in Cassia auriculata and C. goratensis Fres.,
adulteration of oﬃcial sennas,” Annales Pharmaceutiques
Franc ¸aises, vol. 20, pp. 583–587, 1962.
[19] A. Chafer, M. C. Pascual-Mart´ ı, A. Salvador, and A. Berna,
“Supercritical ﬂuid extraction and HPLC determination of
relevant polyphenolic compounds in grape skin,” Journal of
Separation Science, vol. 28, no. 16, pp. 2050–2056, 2005.
[20] G.-Q. He, H.-P. Xiong, Q.-H. Chen, H. Ruan, Z.-Y. Wang,
and L. Traor´ e, “Optimization of conditions for supercritical
ﬂuid extraction of ﬂavonoids from hops (Humulus lupulus
L.),” Journal of Zhejiang University Science B, vol. 6, no. 10, pp.
999–1004, 2005.
[21] C. Yang, Y.-R. Xu, and W.-X. Yao, “Extraction of pharmaceu-
tical components from Ginkgo biloba leaves using supercritical
carbon dioxide,” Journal of Agricultural and Food Chemistry,
vol. 50, no. 4, pp. 846–849, 2002.8 Evidence-Based Complementary and Alternative Medicine
[22] C. D. Stalikas, “Extraction, separation, and detection methods
for phenolic acids and ﬂavonoids,” Journal of Separation
Science, vol. 30, no. 18, pp. 3268–3295, 2007.
[23] O. Sticher, “Natural product isolation,” Natural Product
Reports, vol. 25, no. 3, pp. 517–554, 2008.
[24] Q. Lang and C. M. Wai, “Supercritical ﬂuid extraction
in herbal and natural product studies—a practical review,”
Talanta, vol. 53, no. 4, pp. 771–782, 2001.
[25] E. A. Ryan, M. E. Pick, and C. Marceau, “Use of alternative
medicines in diabetes mellitus,” Diabetic Medicine, vol. 18, no.
3, pp. 242–245, 2001.
[26] “Oﬃce of training and communications DoDIH-center for
drug evaluation and research (CDER), food and drug
administration,” in Guidance for Industry—Diabetes Mellitus:
Developing Drugs and Therapeutic Biologics for Treatment and
Prevention, Services USDoHaH, Ed., p. 34, Rockville, Md,
USA, 2008.
[27] Z. Wang, M. Ashraf-Khorassani, and L. T. Taylor, “Fea-
sibility study of online supercritical ﬂuid extraction-liquid
chromatography-UV absorbance-mass spectrometry for the
determination of proanthocyanidins in grape seeds,” Journal
of Chromatographic Science, vol. 43, no. 3, pp. 109–115, 2005.
[28] Y. Ogasawara, Y. Mukai, T. Togawa, T. Suzuki, S. Tanabe, and
K. Ishii, “Determination of plasma thiol bound to albumin
using aﬃnity chromatography and high-performance liquid
chromatographywithﬂuorescencedetection:ratioofcysteinyl
albumin as a possible biomarker of oxidative stress,” Journal of
Chromatography B, vol. 845, no. 1, pp. 157–163, 2007.
[29] M. C. Whittle, J. F. Stobaugh, and O. S. Wong, “High perfor-
mance liquid chromatographic method for the determination
of homocysteine in human plasma using a water-soluble
phosphine reducing agent and ﬂuorogenic derivatization,”
Chromatographia, vol. 52, pp. S78–S82, 2000.
[30] J. Kajstura, F. Fiordaliso, A. M. Andreoli et al., “IGF-1 overex-
pression inhibits the development of diabetic cardiomyopathy
and angiotensin II-mediated oxidative stress,” Diabetes, vol.
50, no. 6, pp. 1414–1424, 2001.
[31] D. Stepensky, M. Friedman, I. Raz, and A. Hoﬀman,
“Pharmacokinetic-pharmacodynamic analysis of the glucose-
lowering eﬀect of metformin in diabetic rats reveals ﬁrst-pass
pharmacodynamic eﬀect,” Drug Metabolism and Disposition,
vol. 30, no. 8, pp. 861–868, 2002.
[32] B. Patwardhan, “Ethnopharmacology and drug discovery,”
Journal of Ethnopharmacology, vol. 100, no. 1-2, pp. 50–52,
2005.
[33] E. L. Cooper, “eCAM: an emerging linkage with ethnophar-
macology?” Evidence-Based Complementary and Alternative
Medicine, vol. 5, no. 4, pp. 365–366, 2008.
[34] B. Patwardhan, “Ayurveda: the ’Designer’ medicine: a review
of ethnopharmacology and bioprospecting research,” Indian
Drugs, vol. 37, no. 5, pp. 213–227, 2000.
[35] B. M. Schmidt, D. M. Ribnicky, P. E. Lipsky, and I. Raskin,
“Revisiting the ancient concept of botanical therapeutics,”
Nature Chemical Biology, vol. 3, no. 7, pp. 360–366, 2007.
[36] J. R. Senior, “Monitoring for hepatotoxicity: what is the pre-
dictive value of liver ”function” tests?” Clinical Pharmacology
and Therapeutics, vol. 85, no. 3, pp. 331–334, 2009.
[37] L. Pari and M. Latha, “Eﬀect of Cassia auriculata ﬂowers on
blood sugar levels, serum and tissue lipids in streptozotocin
diabetic rats,” Singapore Medical Journal, vol. 43, no. 12, pp.
617–621, 2002.
[38] M. C. Sabu and T. Subburaju, “Eﬀect of Cassia auriculata
Linn.onserumglucoselevel,glucoseutilizationbyisolatedrat
hemidiaphragm,”JournalofEthnopharmacology,vol.80,no.2-
3, pp. 203–206, 2002.
[39] L. Babuin and A. S. Jaﬀe, “Troponin: the biomarker of
choice for the detection of cardiac injury,” Canadian Medical
Association Journal, vol. 173, no. 10, pp. 1191–1202, 2005.
[ 4 0 ]M .H e l m ,J .H a u k e ,A .W e i s s ,a n dL .L a m p l ,“ C a r d i a c
troponin T as a biochemical marker of myocardial injury early
after trauma. Diagnostic value of a qualitative bedside test,”
Chirurg, vol. 70, no. 11, pp. 1347–1352, 1999.
[41] J. Joseph, L. Joseph, S. Devi, and R. H. Kennedy, “Eﬀect
of anti-oxidant treatment on hyperhomocysteinemia-induced
myocardialﬁbrosisanddiastolicdysfunction,”Journal of Heart
andLungTransplantation,vol.27,no.11,pp.1237–1241,2008.
[42] J. Kennedy, “Herb and supplement use in the US adult
population,” Clinical Therapeutics, vol. 27, no. 11, pp. 1847–
1858, 2005.